Anthony Bradley
About Anthony Bradley
Anthony Bradley serves as the Vice President of Design Development at Exscientia, a position he has held since 2021. He has a strong academic background in Chemistry and Pharmaceuticals, holding a PhD from the University of Oxford.
Work at Exscientia
Anthony Bradley has been serving as the Vice President of Design Development at Exscientia since 2021. In this role, he has contributed to the company's focus on artificial intelligence-driven drug discovery. Prior to this position, he held the title of Director of Design Development at Exscientia for nine months in 2020. His tenure at Exscientia has been marked by a commitment to advancing design methodologies in pharmaceutical development.
Education and Expertise
Anthony Bradley earned his Doctor of Philosophy (PhD) in Pharmaceuticals and Drug Design from the University of Oxford, where he studied from 2011 to 2015. He also holds a Master of Chemistry (MChem) degree from the same institution, completed between 2006 and 2010. His academic background provides a strong foundation in drug design and chemistry, which informs his professional work in the pharmaceutical industry.
Background
Before joining Exscientia, Anthony Bradley held various positions that contributed to his expertise in drug design and development. He was a Project Leader for OxXChem at the University of Oxford from 2016 to 2018. He also worked as a Postdoctoral Research Fellow at the University of California, San Diego for one year. His earlier experience includes a role as Head of Structural Bioinformatics at Exscientia from 2018 to 2020 and a PhD position at GSK.
Professional Experience
Anthony Bradley's professional journey includes significant roles in both academia and industry. He interned at Roland Berger Strategy Consultants in 2014, which provided him with insights into strategic consulting. His experience at the Structural Genomics Consortium (SGC) during his DPhil studies further enhanced his research capabilities. This diverse background has equipped him with a comprehensive understanding of the drug development process.